

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) ~~[[A]]~~ An isolated polynucleotide comprising the ~~DNA~~ nucleotide sequence of SEQ ID NO: 1 and 10 to 150 additional consecutive nucleotides immediately upstream from SEQ ID NO: 1, ~~or a substantial functional equivalent of the polynucleotide,~~ wherein the nucleotide sequence of the polynucleotide is contained in SEQ ID NO: 2.
2. (Currently amended) The polynucleotide of claim 1, wherein the DNA sequence of SEQ ID NO: 1 and the additional upstream nucleotides, ~~or the substantial functional equivalent thereof,~~ comprise a region of DNA that is homologous to or identical to a region of DNA comprising a portion of the human dystrophin gene, wherein the DNA sequence of SEQ ID NO: 1, ~~or its substantial functional equivalent,~~ is inverted when compared to the same sequence of the human dystrophin DNA.
3. (Currently amended) The polynucleotide of claim 1, wherein the polynucleotide codes for ~~[[a]] one or more protein or polypeptide~~ proteins or polypeptides that ~~binds~~ bind(s) to the human CD33 protein.
4. (Original) The polynucleotide of claim 1, wherein the polynucleotide codes for a protein or polypeptide that is expressed on a cell surface in vivo.
5. (Currently amended) The polynucleotide of claim 1, wherein the polynucleotide ~~codes for~~ comprises a plurality of translational stop codons.
6. (Canceled)
7. (Canceled)
8. (Currently amended) The polynucleotide of claim 1, wherein the nucleotide sequence of SEQ ID NO: 1 codes for a plurality of translational stop codons.
9. (Currently amended) A regulatory DNA element comprising ~~a polynucleotide selected from the group consisting of (a) the polynucleotide of claim 1, and (b) or a~~ polynucleotide having the sequence of SEQ ID NO: 1, ~~or a substantial functional equivalent thereof.~~
10. (Currently amended) The regulatory element of claim 9, wherein the regulatory element controls the expression of a ~~gene or other DNA sequence~~ nucleic acid to which it is linked.

11. (Currently amended) The regulatory element of claim 9, wherein the regulatory element regulates a transcriptional start site in a ~~the gene or other DNA sequence~~ nucleic acid to which it is linked.

12. (Currently amended) The regulatory element of claim 9, wherein the regulatory element regulates translation of mRNA transcribed from a ~~the gene or other DNA sequence~~ nucleic acid to which it is linked.

13. (Currently amended) The regulatory element of claim 9, wherein the nucleotide sequence of the regulatory element codes for a plurality of translational stop codons.

14. (Currently amended) A ~~polynucleotide~~ nucleic acid that hybridizes to either strand of a ~~polynucleotide selected from the group consisting of (a) the polynucleotide of claim 1, and (b) SEQ ID NO: 1, or a substantial functional equivalent thereof,~~ said nucleic acid comprising an inversion start site of apo-dystrophin-4, wherein a first plurality of nucleotides in said nucleic acid hybridizes 5' to said inversion start site and a second plurality of nucleotides in said nucleic acid hybridizes 3' to said inversion start site, or the complement of such nucleic acid.

15. (Canceled)

16. (Currently amended) A vector comprising a transcription ~~promoter~~ promoter operably linked to a ~~selection from the group consisting of (a) the polynucleotide of claim 1, and (b) or to~~ SEQ ID NO: 1, or a substantial functional equivalent thereof, wherein the sequence of said SEQ ID NO: 1 is inverted with respect to the sequence in normal human dystrophin.

17. (Original) A cell comprising the vector of claim 16.

18. (Currently amended) A cell comprising a ~~selection from the group consisting of (a) the polynucleotide of claim 1, and (b) or a polynucleotide having the nucleotide sequence shown in~~ SEQ ID NO: 1, or a substantial functional equivalent thereof wherein the sequence of said SEQ ID NO: 1 is inverted with respect to the sequence in normal human dystrophin.

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Currently amended) A polynucleotide comprising the DNA sequence of SEQ ID NO: 2, ~~or a DNA sequence that is a substantial functional equivalent of SEQ ID NO: 2, wherein SEQ ID NO: 2 contains SEQ ID NO: 1 or a substantial functional equivalent thereof.~~

23. (Currently amended) The polynucleotide of claim 22, wherein the polynucleotide codes for a polypeptide that cannot be produced in a coupled in vitro transcription-translation system in the absence of SEQ ID NO: 1, ~~or the substantial functional equivalent thereof or the polynucleotide of claim 1.~~

24-36. (Canceled)

37. (Currently amended) A pharmaceutical composition comprising a ~~polynucleotide selected from the group consisting of (a) the polynucleotide of claim 1, and (b) or a polynucleotide having the sequence of SEQ ID NO: 1, or a substantial functional equivalent thereof,~~ and a pharmaceutically acceptable carrier.

38. (Original) The pharmaceutical composition of claim 37 wherein the composition comprises an effective amount of the polynucleotide for treatment of a disorder in which protein truncation plays a part.

39. (Canceled)

40. (Canceled)

41. (New) The polynucleotide of claim 22, wherein SEQ ID NO: 2 codes for a protein or polypeptide that binds to the human CD33 protein.

42. (New) The polynucleotide of claim 22, wherein SEQ ID NO: 2 codes for a plurality of translational stop codons.